Leads the defense of M&A and joint ventures before the DOJ, FTC, and international competition authorities

Counsels customers, suppliers, and competitors adversely affected by proposed transactions

Advises on antitrust litigation, including Sherman Act and Clayton Act Section 7 matters

Counsels clients on distribution issues, contracting arrangements, and other competition-related matters

Mark E. Schreiber focuses his practice on cybersecurity, data breach response, Payment Card Industry (PCI), global privacy coordination, and AI governance. He advises entities facing cross-border data protection, the General Data Protection Regulation (GDPR), privacy frameworks, strategic decisions, cyber assessments and investigations. Mark has led numerous multinational and cross-border matters and internal investigations, including those involving data breaches, data transfer and credit card/PCI matters. He has advised senior management, boards, and special board committees on a variety of investigations, including data breach prevention and response.

Mark has spoken around the world on topics related to data breaches and related defense litigation strategy, overlapping international data protection compliance, and other privacy topics. He has also given cyber, privacy, and AI presentations to delegations from some 80 countries during numerous State Department sponsored international visits. He helped found and was chair for over a decade of the Privacy and Data Protection Group of the World Law Group, an international affiliation of large law firms in some 65 countries, and received the “2012 World Law Group Practice/Industry Group Leader of the Year Award” in recognition of his privacy and data protection work, including managing two global data protection publications. In addition, Mark helped found and was co-chair of the Boston Bar Association’s Privacy Law Committee. He is also a Certified Information Privacy Professional (CIPP/US) and has given a variety of presentations for the International Association of Privacy Professionals (IAPP).

Mark has also practiced, written and lectured widely on topics related to employment law, including presentations to the Flaschner Judicial Institute for judges. Prior to entering private practice, he was the chief trial lawyer for the Massachusetts Commission Against Discrimination (MCAD).

Leads complex healthcare transactions, including mergers and acquisitions, joint ventures, affiliations, management arrangements, and MSO structures

Advises on health information privacy, data use, cybersecurity, and regulatory compliance

Guides digital health, AI, and data-driven initiatives at the intersection of corporate structure, healthcare regulation, and data governance

Advises health insurers, HMOs, provider organizations, and private equity funds on complex regulatory matters and healthcare M&A  

Counsels clients on Medicare Advantage, Medicare Part D, and Medicaid managed care programs  

Helps innovative companies navigate state risk-bearing regulations and structure transactions involving federal and state healthcare programs  

Advises healthcare companies on District of Columbia certificate of need (CON) laws, including CON approvals for new services, ownership changes, and facility closures

Paul Radensky, MD, advises manufacturers at every stage of product development, including the design and monitoring of clinical trials, positioning and applying for Food and Drug Administration (FDA) approval, maintaining regulatory compliance, and obtaining coverage, coding and payment for new technologies by Medicare, Medicaid and other third-party payors.

Paul also advises clinical laboratories on Clinical Laboratory Improvement Amendments (CLIA) and state licensure compliance as well as evolving policies on FDA regulation of laboratory-developed tests. He is a recognized authority on the full range of legal, regulatory and reimbursement issues pertaining to pharmaceutical, biotechnology, medical device, and clinical laboratory development and marketing.

Among recent engagements, Paul currently serves as Washington, DC, representative for several coalitions as well as individual companies that are developers of and stakeholders interested in various diagnostic technologies, including advanced laboratory diagnostics, diabetes testing supplies and drug testing systems. He is also policy and reimbursement counsel to global specialty pharmaceutical wound product, diagnostics imaging and pharmaceutical manufacturers.

Paul’s background as a clinical researcher and medical practitioner informs his practical and scientific understanding of product manufacturers and clinical laboratories. He is board certified in internal medicine.

Eric Zimmerman is a recognized Medicare law and policy authority and registered lobbyist who represents clients before Congress and administrative agencies, and helps clients navigate federal legislative and regulatory processes related to Medicare coverage, coding, reimbursement and compliance. He primarily counsels and represents hospitals and health systems, ambulatory surgery centers, clinical laboratories, pharmaceutical, biotechnology and device manufacturers and suppliers, medical trade associations and professional societies.

Allison Wilkerson focuses her practice on employee benefits matters. She has extensive experience handling issues pertaining to the Employee Retirement Income Security Act of 1974 (ERISA) and employee stock ownership plans (ESOPs).

With respect to ERISA, Allison focuses on compliance issues and the Internal Revenue Code related to employee benefits, including qualified plans, nonqualified plans, and executive and deferred compensation. While advising employers on the design, implementation and administration of tax-qualified retirement plans and nonqualified retirement plans, Allison provides relevant guidance as to administrative and operational matters, and assists clients with various benefit plan correction programs offered by the Department of Labor (DOL) and Internal Revenue Service (IRS). Allison also has advised employers with respect to issues raised in connection with corporate mergers, acquisitions and divestitures as they relate to the various benefit plans maintained by the affected corporate entity or entities.

Allison focuses her ESOP practice on the design and implementation of ESOP transactions and provides ongoing legal counsel to ESOP-owned companies. She has been involved in hundreds of transactions, including leveraged buyouts, mergers, acquisitions, and the structuring and financing of ESOPs using private equity. She has advised employers on the implementation of nonqualified plans and executive compensation arrangements that complement the employee ownership structure and culture inherent in an ESOP-owned company. Allison also represents independent fiduciaries in their role as purchaser in an ESOP transaction as to their legal duties with respect to their representation of ESOP participants and beneficiaries.

Allison writes and speaks frequently on ERISA and ESOP issues.

Defends mergers and competitor collaborations in the healthcare industry through federal and state antitrust enforcement agency review

Advises on ongoing conduct and antitrust compliance matters, including provider contracting networks, joint purchasing arrangements, information exchanges, and other forms of competitor collaborations

Advises healthcare providers, from startups to established market leaders, on complex federal and state regulatory and reimbursement matters

Serves as a national authority on the 340B Drug Pricing Program

Counsels clients on fraud and abuse laws, Medicare provider-based and co-location rules, pharmacy laws and licensure, graduate medical education, rural providers, and federally qualified health centers

Advises on the development of innovative healthcare delivery models